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Early Aβ Reduction Prevents Progression
of Cerebral Amyloid Angiopathy
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Objective: Clinical trials targeting β-amyloid peptides (Aβ) for Alzheimer disease (AD) failed for arguable reasons that
include selecting the wrong stages of AD pathophysiology or Aβ being the wrong target. Targeting Aβ to prevent
cerebral amyloid angiopathy (CAA) has not been rigorously followed, although the causal role of Aβ for CAA and
related hemorrhages is undisputed. CAA occurs with normal aging and to various degrees in AD, where its impact and
treatment is confounded by the presence of parenchymal Aβ deposition.
Methods: APPDutch mice develop CAA in the absence of parenchymal amyloid, mimicking hereditary cerebral hemor-
rhage with amyloidosis Dutch type (HCHWA-D). Mice were treated with a β-site amyloid precursor protein cleaving
enzyme 1 (BACE1) inhibitor. We used 3-dimensional ultramicroscopy and immunoassays for visualizing CAA and assessing
Aβ in cerebrospinal ﬂuid (CSF) and brain.
Results: CAA onset in mice was at 22 to 24 months, ﬁrst in frontal leptomeningeal and superﬁcial cortical vessels
followed by vessels penetrating the cortical layers. CSF Aβ increased with aging followed by a decrease of both Aβ40
and Aβ42 upon CAA onset, supporting the idea that combined reduction of CSF Aβ40 and Aβ42 is a speciﬁc biomarker
for vascular amyloid. BACE1 inhibitor treatment starting at CAA onset and continuing for 4 months revealed a 90% Aβ
reduction in CSF and largely prevented CAA progression and associated pathologies.
Interpretation: This is the ﬁrst study showing that Aβ reduction at early disease time points largely prevents CAA in the
absence of parenchymal amyloid. Our observation provides a preclinical basis for Aβ-reducing treatments in patients at
risk of CAA and in presymptomatic HCHWA-D.
ANN NEUROL 2019;00:1–11
Cerebral amyloid angiopathy (CAA) is common in theelderly and associated with cerebrovascular alterations
and an increased risk of intracerebral bleeding.1,2 CAA is
thought to contribute to hemorrhagic stroke but also to
compromise normal brain function, including cognition.
It progressively increases with aging, both in frequency
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and severity, and is also commonly observed in Alzheimer
disease (AD). CAA is caused by deposition of aggregated
β-amyloid peptides (Aβ) within cerebral vessels.1 The most
prominent Aβ isoform deposited is Aβ40 (the Aβ species
ending at amino acid 40). This is in contrast to the paren-
chymal plaques in AD brain that contain primarily the
Aβ42 isoform.3 CAA can develop sporadically or can be
linked to distinct mutations in the Aβ precursor protein
(APP). Patients with an APP E693Q mutation develop
severe CAA in the virtual absence of compact (congophilic)
parenchymal plaques (hereditary cerebral hemorrhage with
amyloidosis Dutch type [HCHWA-D]).4,5
Similar to humans, different Aβ plaque-forming
APP transgenic mouse models also develop CAA to quite
a different degree.6 In an attempt to generate a “pure”
CAA model, we took advantage of the HCHWA-D muta-
tion, which resulted in an especially clean recapitulation of
the CAA-only phenotype in APPDutch mice.7 These mice
develop CAA in leptomeningeal and cortical vessels
together with smooth muscle and basement membrane
disruptions, gliosis, and microhemorrhages. As in humans,
vascular amyloid in APPDutch mice consists largely of
Aβ40. Interestingly, amyloid deposition in APPDutch
mice can be directed to parenchymal plaques upon addi-
tional expression of mutated presenilin 1 that shifts Aβ
generation to the longer Aβ42 isoforms.8 This observation
further emphasizes the close mechanistic link between
CAA and parenchymal amyloid and their corresponding
clinically distinct phenotypes.9
Currently, no treatment for CAA is available. In fact,
some Aβ immunotherapies both in AD patients and mouse
models resulted in increased CAA, blood vessel–associated
bleeding, or amyloid-related imaging abnormalities, even
with overall reduced Aβ deposition. These observations sug-
gest a complex, dynamic interaction between the different
Aβ isoforms and assemblies as well as antibodies.10–14 To
focus on the treatment of CAA and to avoid interference by
parenchymal Aβ deposition, we used the APPDutch mouse
model. We further focused on very early disease stages and
thus aimed at preventing CAA progression rather than clear-
ing vascular Aβ deposition with putative side effects. To this
end, we used an inhibitor of β-site APP-cleaving enzyme
1 (BACE1), which decreases Aβ production. Our results
demonstrate that Aβ reduction at such early time points
considerably delays the development and progression of
CAA and associated pathologies.
Materials and Methods
Mice
APPDutch mice overexpress E693Q mutated human APP751
under the neuron-speciﬁc murine Thy-1 promoter element.7
The mice have been generated and maintained on a C57BL/6J
(B6) background. Animals were kept in standard housing conditions
with a 12-hour dark/light cycle with free access to food and water.
The mean life span of APPDutch mice is about 26 to 28 months,
similar to their nontransgenic littermates and similar to B6 mice.7,15
CAA onset in female APPDutch mice is around 22 to 24 months,
and in males CAA onset is delayed.7 Thus to increase the chance
that the mice in the present study would develop robust CAA, only
female mice were included in the treatment study. All experiments
were in compliance with protocols approved by the local Animal
Care and Use Committees (N5/13, N2/15, and N10/15). The
exact number of mice used for each experiment is given in the ﬁgure
legends.
BACE1 Inhibitor Treatment
The BACE1 inhibitor NB-360 (Novartis, Basel, Switzerland) was
mixed into standard food pellets (0.5g NB-360/kg food pellets).
This dose yields brain exposure similar to 100μmol/kg orally, as
previously described.16,17 Average plasma and brain levels of NB-
360 over 24 hours for this dose were 1.2 and 4.8μM, respec-
tively.17 Two batches of female APPDutch mice were fed with
pellets containing the BACE1 inhibitor NB-360 between ages
23.5 and 27.5 months. Age-matched female control mice received
control pellets without the drug for the same time period. Food
pellets were available ad libitum until the mice were killed. Ani-
mals were monitored daily by animal caretaker staff and 3 times a
week by the researchers during the entire treatment period. There
were no differences in food consumption and body weight
between BACE1 inhibitor–treated mice and control mice.
Cerebrospinal Fluid and Brain Collection
Cerebrospinal ﬂuid (CSF) collection has been described previously
and was always done between 10 AM to 2 PM on a given day to min-
imize circadian CSF Aβ variations.17–19 Deeply anesthetized mice
(ketamine at 100mg/ml and xylazine at 10mg/ml) were kept on a
heating pad during the whole procedure to avoid hypothermia.
With the help of a dissecting microscope, the skin was opened and
the underlying tissue and neck muscles were separated to expose the
cisterna magna. The dura mater was perforated, and the CSF was
collected with a GELoader Tip (Eppendorf, Hamburg, Germany).17
CSF samples were immediately centrifuged at 2,000 × g for
10 minutes (at room temperature) and inspected for blood contami-
nation. Aliquots were stored at −80C until use. After CSF collec-
tion, mice were perfused for 4 minutes with phosphate-buffered
saline (PBS) at 4C. The brain was removed, and one hemisphere
was snap frozen on dry ice. The other hemibrain was immersion
ﬁxed in 4% paraformaldehyde (in 0.1M PBS for 48 hours at 4C),
immersed in 30% sucrose in PBS for additional 48 hours at 4C,
and then frozen in 2-methylbutane. Both hemispheres were stored
at −80C until use.
Ultramicroscopy
To visualize the 3-dimensional (3D) distribution of vascular
amyloid in APPDutch mouse brain, mice (n = 4, 28–31 months
of age) were injected twice (24-hour interval) intraperitoneally
with 75μl of 1% methoxy-X04 (courtesy of W. Klunk, Univer-
sity of Pittsburgh)20 in dimethyl sulfoxide. Two hours after the
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last injection, animals were deeply anesthetized and perfused
transcardially with the following ice-cold solutions: 10ml of
heparin-sodium (5 IE/ml; B. Braun Melsungen AG, Melsungen,
Germany) in PBS, 20ml of 1% paraformaldehyde in PBS, 20ml
of 0.001% ﬂuorescein isothiocyanate (FITC)-labeled Lycopersicon
esculentum lectin (tomato lectin; Vector Laboratories, Burlin-
game, CA) in PBS, and ﬁnally 50ml of 4% paraformaldehyde in
PBS. Subsequently, brains were prepared and postﬁxed in 4%
paraformaldehyde in PBS at 4C overnight, followed by 3 washes
in PBS. The tissue was dehydrated in an ascending series of etha-
nol concentrations (50%, 70%, 80%, 96% for 24 hours,
4 × 100% for 24 hours) and transferred into the peroxide-free
clearing medium, containing 1 part benzyl alcohol and 2 parts
benzyl benzoate.21 The brains were kept in this clearing solution
until they became transparent.22 Two-sided light sheet illumina-
tion was performed using a Sapphire diode laser with λ = 488nm
(Coherent, Dieburg, Germany; 500mW) and a LQC 180E
diode laser with λ = 405nm (Newport, Irvine, CA; 180mW).
The LQC 180E diode laser was integrated into the setup by
using a dichroic mirror.23 Unwanted excitation light was blocked
in the observation pathway by an ET 525/50 bandpass ﬁlter
(AHF Analysentechnik, Tübingen, Germany) for the 488nm
laser and an E 455 long pass ﬁlter (Chroma Technology, Bellows
Falls, VT) for the 405nm laser. Image recording was performed
using Olympus XL Fluor objectives (2×: N.A. 0.14; 4:
N.A. 0.28 (N.A. stands for Numerical Aperture); Olympus,
Tokyo, Japan) and a 12-bit CCD camera with 2,048 ×
2,048-pixel resolution (Cool Snap K4; Roper Scientiﬁc,
Planegg, Germany). For visualizing the entire brain, a 0.63×
postdemagniﬁcation was combined with the 2× objective. The
3D image reconstruction was performed via Amira 5.2 (Visage
Imaging, Berlin, Germany).
Aβ Measurement in CSF and Brain
Aβ40 (Aβx–40) and Aβ42 (Aβx–42) concentrations in CSF and
brain extracts (frozen hemisphere, see previous description) were
determined with an electrochemiluminescence-linked immunoas-
say (V-PLEX Aβ Peptide Panel 1 [6E10] Kit; Meso Scale Dis-
covery, Gaithersburg, MD). CSF was diluted 1:14 in buffer
(Diluent 35; Meso Scale Discovery) and analyzed according to
the manufacturer’s instructions, as described previously.17 Fore-
brains (hemibrains without cerebellum) were homogenized at
10% (weight/volume) in homogenization buffer (50mM Tris
pH 8.0, 150mM NaCl, 5mM EDTA, and protease/phosphatase
inhibitor cocktail from Thermo Fisher Scientiﬁc, Waltham, MA)
at 4C using 7ml lysing tubes with 2.8mm ceramic beads and a
tissue homogenizer (Precellys; Bertin Technologies, Montigny-le-
Bretonneux, France) twice at 5,500 rpm for 10 seconds (with a
break of 10 seconds). The homogenized brain tissue was aliquoted
and stored at −80C until use. For Aβ measurements, the homog-
enates were extracted as follows: aliquots were thawed on ice,
mixed 1:3.2 with cold formic acid (FA) at minimum 96% purity
(Millipore; Sigma, St Louis, MO), sonicated for 35 seconds at
4C, and spun at 25,000 × g at 4C for 1 hour. The supernatant
was collected as the “FA-soluble fraction” and equilibrated (1:20)
in neutralization buffer (1M Tris base, 0.5M Na2HPO4, 0.05%
NaN3). FA-soluble total brain extracts were diluted up to 1:4 in
buffer (Diluent 35; Meso Scale Discovery) before measurement.
Data analysis used MSD Discovery Workbench software 2.0.
Internal reference samples were used as controls in every plate.
Histology and Immunohistochemistry
After freezing, ﬁxed hemispheres were cut into serial 25μm-thick
coronal sections using a freezing-sliding microtome (Leica,
Nussloch, Germany). The sections were collected in tissue
cryoprotection solution (35% ethylene glycol, 25% glycerol in
PBS) and stained immunohistochemically according to previ-
ously published protocols using anti-Aβ polyclonal antibody
CN6 (1:2,000), a follow-up version of CN3.24 Microglia were
visualized using a rabbit polyclonal antibody against ionized
calcium binding adapter molecule 1 (Iba1; Thermo Fisher Sci-
entiﬁc, catalogue no. PA5-21274) in combination with Congo
red staining.7,24 The Prussian blue reaction of Perls was used to
visualize ferric iron in hemosiderin.25,26
For direct comparison of the 2 different Aβ staining approaches
(ultramicroscopy vs Aβ immunohistochemistry), identical brain sec-
tions were ﬁrst stained with methoxy-X04 (provided by W. Klunk,
Pittsburgh, PA) followed by a subsequent immunohistochemical
staining for Aβ (CN6). Staining with methoxy-X04 included
3 washes in PBS, a 30-minute incubation in 0.3% Triton X-100 in
PBS, followed by incubation with a staining solution of 4% vol-
ume of 10mg/ml methoxy-X04 in dimethyl sulfoxide and 7.7%
volume CremophorEL (Sigma-Aldrich, Steinheim, Germany) in
88.3% volume PBS for 30 minutes at room temperature, with sub-
sequent PBS washes and ﬁnal mounting with FluorSave Reagent
(Merck Chemicals, Darmstadt, Germany). After images of
methoxy-X04–positive vessels were acquired with a Zeiss Axioplan
2 ﬂuorescent microscope (Carl Zeiss MicroImaging, Jena, Ger-
many) using ﬁlter set 10 (BP 450-490 for excitation and BP
515-565 for emission; Zeiss) with a Zeiss AxioCam HR digital
color camera in black-and-white mode (standard mono) and a
Zeiss Plan-Neoﬂuar 10×/0.3 objective, coverslips were removed
and Aβ immunostaining was performed. Subsequently, bright-ﬁeld
images of Aβ immunohistochemical staining at the identical posi-
tions were acquired using no ﬁlter and the RGB mode (standard
color) of the AxioCamHR camera.
For double labeling of Aβ and smooth muscle actin
(SMA), sections were incubated in citrate buffer (0.04M sodium
citrate dihydrate and 0.06M citric acid in distilled water, pH 6)
for 30 minutes at 90C. After a washing step with PBS, sections
were treated with proteinase K (1μg/μl in 50mM Tris base and
1mM calcium chloride in distilled water, pH 7.6) for 30 minutes
at 37C. Sections were incubated for 3 days at 4C with CN6
(anti-Aβ; 1:1,000; see previous description) and anti-alpha SMA
antibody ab21027 (goat polyclonal, 1:200; Abcam, Cambridge,
UK). Secondary antibodies were donkey anti-rabbit Alexa Fluor
568 (A10042, Invitrogen, Carlsbad, CA), and donkey anti-goat
Alexa Fluor 488 (705-545-147; Dianova, Hamburg, Germany),
both diluted 1:250. We used 40-6-diamidino-2-phenylindole
(DAPI) as a nucleic acid counterstain at 1:1,000 (D9542; Sigma,
Deisenhofen, Germany). Sections were mounted with Dako
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Fluorescence Mounting Medium (S3023; Biozol Diagnostica,
Eching, Germany).
CAA Quantiﬁcation
CAA was quantiﬁed on Aβ-immunostained (CN6 antibody) sets of
every 12th systematically sampled 25μm-thick coronal section through
the ﬁxed hemisphere (see previous description). The number and
severity of Aβ-positive vessels throughout the neocortex including the
leptomeningeal vessels was manually assessed by a rater blinded to the
experimental groups using a Zeiss Axioskop 2 microscope with a 10×
objective (Zeiss, Oberkochen, Germany) as previously described in
detail.27 In short, CAA frequency refers to the number of Aβ-
immunostained vessel proﬁles with neighboring proﬁles considered as
separate vessels. Severity was graded in 3 categories: CAA grade 1, Aβ-
immunoreactivity restricted to parts of the vessel wall; CAA grade
2, Aβ-immunoreactivity throughout the vessel wall and/or extending
focally to the surrounding neuropil; CAA grade 3, extensive inﬁltration
of Aβ into the parenchyma with a complete “amyloid coat” around the
vessel.27 If CAA frequency was zero (n = 2 animals), vessel severity was
also set to zero. CAA score for an animal was calculated by multiplying
CAA frequency with CAA severity.27
Quantiﬁcation of Cerebral Hemorrhage
Perls Berlin blue–stained hemosiderin-positive microglia were
quantiﬁed on an additional set of every 12th systematically sampled
section throughout the neocortex and the overlying leptomeningeal
vessels of the ﬁxed hemisphere. Hemosiderin-positive staining in
the vicinity of vessels and clusters of positive microglia were counted
as indicators of microbleeds. Frequency of microbleeds and severity
of microbleeds was assessed as previously described,11 and the rater
was blinded toward experimental groups. The microhemorrhage
score was calculated by multiplying microbleed frequency with
microbleed severity.11
Quantiﬁcation of Microgliosis
Congo red–positive vessels with associated clusters of activated (hyper-
trophic) Iba1-positive microglia were counted in the area of the frontal
cortex supplied by the medial cerebral artery (and thus robustly
affected by CAA). Therefore, the 3 “frontal sections” out of the set of
every 12th systematically sampled brain section were selected (bregma
anterior-posterior 0.7–1.7mm) and scanned using an automated Zeiss
Axioscan.Z1 slide scanner. Images were captured at ×10 magniﬁca-
tion. For each ﬁeld of view, z stacks were acquired, and extended
depth of focus images were automatically stitched to produce a full
image, which was imported into Fiji (https://imagej.net/Fiji).28 An
ImageJ script was written to automate the microglia color-coding pro-
cess, as follows: the red channel of the RGB image was used to exclude
any Congo red staining from the classiﬁcation. A preselected threshold
was then used to identify microglial cells. Using the built-in “Analyze
Particles” function, microglia structures were marked as regions of
interest (ROI); the areas of each of the ROIs were colorized on arbi-
trary ranges (red: area < 50μm2; yellow: 50μm2 ≤ area < 80μm2;
green: 80μm2 ≤ area < 120μm2; blue: area ≥ 120μm2). The resulting
colorized ROIs were overlaid with the original RGB image. Thus,
clusters of activated microglia around CAA became easily recognizable
and were counted manually by a rater blinded toward experimental
groups.
Quantiﬁcation of Smooth Muscle Cells
SMA and Aβ double-labeled sections (see previous description)
were analyzed with a Zeiss LSM 510 META confocal micro-
scope (40× oil-immersion Plan Neoﬂuar objective, 1.3 NA;
Axiovert 200M). Laser lines 488nm and 543nm were used to
excite Alexa Fluor 488 and Alexa Fluor 568, respectively, and
405nm for DAPI counterstain. Imaging parameters were slightly
adjusted for individual vessels/images to prevent overexposure.
Care was given to always acquire the maximum area covered by
SMA. Images of 18 to 20 vessels of the different CAA severity
grades (note that CAA grade 3 of NB-360–treated mice was rare
and only 5 vessels could be sampled) and also of unaffected vessels
were acquired in a subset of animals from the NB-360–treated
and age-matched control mice (n = 5 per group). Only penetrat-
ing vessels of similar/comparable cutting plane and diameter were
selected. Images were analyzed in a semiautomated way using a
customized ImageJ script in Fiji to quantify the areas of CAA and
SMA in the sampled blood vessels. Residual noise was automatically
removed by basic despeckle ﬁltering, and then the blood vessel area
was manually outlined and a preselected ﬁxed threshold was set for
each channel. The area of pixels above this threshold was measured
within the selected ROI. The measured SMA area was normalized
to the total SMA + CAA area for further analysis.
Statistical Analysis
Prism (v6.0; GraphPad Software, San Diego, CA) was used for
statistical analyses and graphics. Normal distribution was assessed
using the Shapiro–Wilk test. If individual CSF and brain Aβ
values were below the assay detection limit, a ﬁxed value (detec-
tion limit of the plate where the sample was measured/√2) was
imputed. Imputed values were not considered for statistical anal-
ysis of the Aβ42/40 ratio measurements. In all cases, statistical
signiﬁcance was set at p < 0.05.
Results
Distribution and Progression of CAA in Aging
APPDutch Mice
In a previous study, CAA was ﬁrst detected in APPDutch
mice at 22 to 24 months of age.7 To better appreciate its
distribution and progression in the entire mouse brain, we
examined CAA in sets of systematically sampled Aβ-
immunostained sections of aged APPDutch mice (n = 20;
age = 23–28.5 months). Additional mice of advanced age
(n = 4; age = 28–31 months) were subjected to ultra-
microscopy29 using FITC-conjugated tomato lectin in
combination with the amyloid dye methoxy-04 to visual-
ize the entire vasculature in 3D (Fig 1, Supplemen-
tary Video; see Materials and Methods section for details).
Consistent with our previous study, histological analysis
revealed considerable variability in the onset and amount
of CAA in these mice.7 However, in all cases, CAA ﬁrst
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FIGURE 1: Three-dimensional (3D) visualization of cerebral amyloid angiopathy (CAA) distribution and progression in APPDutch mice
with ultramicroscopy. Two aged APPDutch mice at different stages of CAA deposition are shown. (A, B) CAA deposition was ﬁrst
observed in the middle cerebral artery and its superﬁcial leptomeningeal branches (arrowheads; moderately affected female APPDutch
mouse; 30 months old; B is the lateral view of A). Minor CAA deposition was observed in the branches originating from the anterior
cerebral artery (arrows). Note that posterior regions of the neocortex and the cerebellum were largely spared. (C, D) At later stages,
CAA progressed along branches of the middle cerebral artery (eg, ventral branches, arrowheads) and was also observed in the
superﬁcial branches of the middle and posterior internal frontal arteries (arising from the anterior cerebral artery; arrows). At these later
stages, CAA deposition extended towards smaller site branches and descending parenchymal arteries. The posterior cortical regions
and the cerebellum remained largely spared (shown is a more severely affected male APPDutch mouse; 31 months old; D is the lateral
view of C). (E) High magniﬁcation of the middle cerebral artery (from panel B). Although the main branches (arrowheads) were affected
with CAA, smaller site branches (arrows)were relatively spared. (F) High magniﬁcation and rotated view of panel E; for 3D visualization,
see the Supplementary Video. Severe CAA deposition was observed in the superﬁcial branches, but at this moderate stage of disease
only few descending parenchymal vessels were positive for CAA (arrowheads). Examples of unaffected penetrating arteries are marked
with arrows (green: CAA stained with methoxy-X04; red: vessel counterstaining with ﬂuorescein isothiocyanate–conjugated tomato
lectin; all images are projections of 3D views with the following relative zoom factors: 0.4 (A, C; dorsal views), 0.5 (B, D; lateral views),
1.0 (E), and 1.6 (F). Overlap of a histological methoxy-X04 CAA staining (G) with a subsequent immunohistochemical staining for
β-amyloid peptides of the identical section (H). This affected vessel within a 25μmbrain section is from a female 28-month-old APPDutch
mouse; seeMaterials andMethods section for details. Scale bar is 100μm.
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appeared in superﬁcial vessels of the cortex followed by
vessels penetrating the cortical layers. Parenchymal deposi-
tion was very rare and if found it was of diffuse nature.
Occasionally, CAA was also seen in the thalamus, the hip-
pocampal formation, and the amygdala.
Ultramicroscopy revealed CAA ﬁrst within the mid-
dle cerebral artery and its branches, with minor deposition
in the branches originating from the anterior cerebral
artery. The posterior regions of the neocortex and the cer-
ebellum remained mostly unaffected (see Fig 1A–D; Sup-
plementary Video). Within the affected arteries, most
CAA was detected in the main superﬁcial branches, and
smaller side branches were spared (shown for the middle
cerebral artery, see Fig 1E, F). In more heavily affected
animals, branches also showed prominent CAA, and Aβ
deposition was observed in descending cerebral arteries
with an increased overall vessel surface occupied with amy-
loid. As expected, high overlap between the methoxy-X04
staining used for ultramicroscopy and Aβ-positive immu-
nostaining was found. High magniﬁcation of methoxy-
X04 stained vessels depicted the characteristic clustered
staining pattern of CAA in between vascular smooth mus-
cle cells.
Age-Related Increase in Brain Aβ
For biochemical analyses, 4 new groups of female
APPDutch mice (3, 12, 23.5, and 27.5 months of age)
were examined (Fig 2). Results revealed that FA-soluble
Aβx–40 and Aβx–42 in brain (ie, Aβ species ending with
amino acid 40 and 42) remained unchanged and at low
level until the age of 23.5 months (Fig 3A, B). At that
time, some animals revealed a notable increase. This is
consistent with our current and previous histological
analysis7 reporting CAA onset between age 22 to
24 months. CSF Aβ increased until 23.5 months (the
time of CAA onset) with a decrease thereafter (see Fig 3D,
E). The Aβ42/40 ratio remained unchanged during aging
in both brain and CSF (see Fig 3C, F).
BACE Inhibition Prevented CAA Progression
APPDutch mice were treated with BACE1 inhibitor NB-
36016 starting at 23.5 months of age for 4 months (see
Fig 2). NB-360 strongly reduced Aβ generation, which
was revealed by a decrease of both CSF Aβ40 and Aβ42
by more than 90% compared to controls (see Fig 3D,
E). This inhibition translated into a > 65% reduction of
insoluble (ie, FA soluble) Aβ40 and Aβ42 (see
Fig 3A, B).
Histological analysis indicated only minor CAA deposi-
tion at the 23.5-month time point, and CAA was mainly
present in superﬁcial cerebral arteries (see Fig 4A). Thereafter
in untreated control mice, CAA considerably increased both
in frequency and severity consistent with the histological time
course and the ultramicroscopy data described. In NB-360–
treated mice and in agreement with the biochemical analysis
(see Fig 3), histological staining showed a strong reduction of
the frequency and the severity of CAA compared to non-
treated controls (see Fig 4B–D). Of note, NB-360-treated
mice had less CAA in cortical parenchymal vessels, and in
particular in branches originating from the anterior cerebral
as well as middle cerebral artery consistent with a delay of
CAA progression in BACE1 inhibitor treated mice.
CAA-Associated Pathologies
Clustering of activated microglia around vessels with mod-
erate to severe CAA was observed in all affected animals
(see Fig 5A, B), an observation in line with our previous
analysis.7 Consistent with the greatly reduced CAA in
NB-360–treated mice, there was a signiﬁcant reduction of
CAA-associated microgliosis in the 27.5-month-old NB-
360–treated mice compared to the age-matched control
mice (see Fig 5C).
Microhemorrhages were rare and associated only with
a small subset of amyloid-laden vessels. Large intracerebral
bleeding was not observed. No difference in micro-
hemorrhages between the 27.5-month-old NB-360–treated
mice versus the nontreated control mice was found
(see Fig 5D).
Progressive Aβ deposition in the vasculature (increas-
ing CAA severity grade) led to a loss of smooth muscle
cells in both the NB-360–treated 27.5-month-old mice
and the control mice (see Fig 5E, F). However, since all
CAA severity grades were drastically reduced in the NB-
360–treated mice compared to the age-matched control
FIGURE 2: Schematic overview of aging cohorts and
experimental groups. Female APPDutch mice were aged and
analyzed at 3, 12, 23.5, and 27.5 months of age. An
additional group of female 23.5-month-old APPDutch mice
was fed with food pellets containing the β-site amyloid
precursor protein cleaving enzyme 1 (BACE1) inhibitor NB-
360 (BI) from age 23.5 to 27.5 months (n = 8, 9, 11, 17, and
19 for the 3, 12, 23.5, 27.5, and BI 27.5 month-old group;
the higher number of mice in the 27.5-month-old groups was
chosen by anticipating a higher variability). The group
numbers are also mentioned again in the legends of all
ﬁgures. Mice that died before the end of the experiment
(n = 5 for the untreated mice and n = 6 for the BI treated
mice) were not included in the analysis. Note that the mean
life span of the mice is between 26 and 28 months, and thus
the death of some animals was expected.
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mice, results reveal that BACE1 inhibition also prevented
vessel-associated smooth muscle cell loss (see Fig 5G-I).
Discussion
Vascular deposition of Aβ detectable as congophilic CAA
occurs with normal aging and to varying degrees also in
AD, where its impact and treatment is confounded by the
presence of parenchymal Aβ deposition. CAA is associated
with disruption of vascular structure and hemorrhages and
compromises brain function in sporadic and hereditary
(eg, HCHWA-D) forms.30 Here, we have studied the
effect of Aβ reduction at the time of CAA onset in an ani-
mal model (APPDutch mice) that develops CAA in the
absence of parenchymal amyloid deposition.7
To this end, we have expanded previous work of CAA
development in the APPDutch mouse model7 and have
complemented Aβ-immunostaining on serial histological sec-
tions with 3D ultramicroscopy, which enabled visualization
of the entire cortical vasculature with CAA. CAA-positive
leptomeningeal vessels and vessels penetrating the cerebral
cortex were mainly observed in frontal (and parietal) regions
with posterior regions much less affected. CAA was also
found occasionally in the thalamus, hippocampal formation,
and amygdala. Except for the predilection for the frontal rela-
tive to the posterior cortices, CAA distribution in the mice
resembled the observations in HCHWA-D patients, where
CAA consistently is observed in meninges and cerebral cortex
and only to a lesser degree in basal ganglia, hippocampus,
and brainstem.31 In APPDutch mice, vessels were sequen-
tially affected starting at the main cerebral arteries and pro-
gressing towards smaller branches and descending
parenchymal arteries. First deposition of CAA was found in
the middle cerebral artery and its branches, and the anterior
cerebral artery was only later affected. Over time, the area
covered with amyloid increased within all affected vessels. A
similar development of CAA, with an anterior-to-posterior
and large-to-small vessel gradient of involvement has been
described in other transgenic mouse models despite the
FIGURE 3: Levels of brain and cerebrospinal ﬂuid (CSF) aggregated β-amyloid peptides (Aβ) in aging APPDutch mice and after
treatment with a β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor. Female APPDutch mice were aged, and half
the mice (see schema in Fig 2) were fed with either control food pellets or pellets containing a BACE1 inhibitor NB-360 (BI) starting at
age 23.5 months until 27.5 months. (A–C) Aβx–40 and Aβx–42 levels in brain were largely reduced by BI treatment (Mann–Whitney
U test comparing 27.5-month-old groups: U = 67.0 [p = 0.0022] and U = 73.0 [p = 0.0043], respectively). No difference in brain
Aβ42/40 ratio after BI treatment was found (C). (D–F) CSF Aβ increased from 3 to 23.5 months of age and decreased thereafter;
Kruskal–Wallis H test for the 4 age groups, df = 3, CSF Aβx–40: H corrected for ties = 9.32 (p = 0.025); post hoc Dunn multiple
comparisons test was employed for group comparisons, which were always conducted between the 3-month group with all other age
groups: 3 versus 23.5 months, p = 0.017, all others p > 0.05 (D); CSF Aβx–42: H corrected for ties = 10.19 (p = 0.017), 3 versus
23.5 months, p = 0.021, all others p > 0.05 (E). Treatment with NB-360 (BI) signiﬁcantly decreased CSF Aβx–40 and Aβx–42 levels
compared to age-matched 27.5-month-old controls (Mann–Whitney U test comparing 27.5-month-old groups, U = 5.5 and U = 14.0,
respectively; p < 0.0001). The difference in CSF Aβ42/40 ratio after BI treatment was not assessed due to the majority of imputed
values within the BI group (F). All data are represented as median with interquartile range; n = 8, 9, 11, 17, and 19 for the 3, 12, 23.5,
27.5 and 27.5 BI group (see also Fig 2). *p < 0.05, **p < 0.01, ***p < 0.001.
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additional Aβ deposition in the brain parenchyma in these
mice.6,32
In CSF of APPDutch mice, we observed an age-
related increase of Aβ until ﬁrst Aβ deposition with a
decrease of Aβ thereafter. This is reminiscent to the
biphasic CSF Aβ levels in other APP transgenic mice, that
is, an increase in early phases and a decrease upon onset of
amyloid deposition.19 Interestingly, the decrease in CSF
Aβ upon deposition was equal for Aβ40 and Aβ42 in the
APPDutch model, and it appears much stronger for Aβ42
compared to Aβ40 in the APP transgenic mouse models
with primarily parenchymal amyloid deposition.19 A simi-
lar observation has been made in patients diagnosed with
CAA33,34 and was recently extended to presymptomatic
HCHWA-D mutation carriers.35 Our observations sug-
gest that even in mice, a comparable reduction of both
CSF Aβ40 and 42 is a suited and speciﬁc biomarker for
vascular amyloid deposition.
Treatment of aged APPDutch mice 23.5 to
27.5 months with NB-360 led to a more than 90%
reduction of CSF Aβ and demonstrates that BACE1
inhibition is also very effective in aged mice. Consis-
tently, NB-360 remarkably prevented the increase in
insoluble Aβ and the progression of CAA. Indeed, vascu-
lar amyloid was rarely seen (or at least greatly reduced) in
the cortical parenchyma–penetrating branches of the
anterior and middle cerebral arteries in NB-360–treated
APPDutch mice. No shift of Aβ to other forms of
deposits such as diffuse plaques was observed. CAA-
associated microgliosis and smooth muscle cell loss were
reduced in the treated mice, indicating a beneﬁcial effect
of the treatment. The number of microhemorrhages was
unchanged between treated and control groups, and the
lack of a reduction may be explained by the paucity of
robust CAA-associated bleedings at this early stage
of CAA.
FIGURE 4: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibition prevents age-dependent cerebral amyloid
angiopathy (CAA) progression. Female APPDutch mice (see treatment schema, Fig 2) were fed with either food pellets
containing the BACE1 inhibitor NB-360 (BI) or control pellets from age 23.5 to 27.5 months. (A) CAA deposition (immunostaining
for aggregated β-amyloid peptides) on coronal hemibrain sections is exemplarily shown for each group. An increase in CAA from
23.5 to 27.5 months was observed, which was in line with the histological time course and the ultramicroscopy in aging
APPDutch mice. In contrast to control-treated mice, BI-treated mice showed an overall reduction in the amount of CAA,
especially in branches originating from the anterior cerebral artery as well as the middle cerebral artery. Inserts depict CAA
deposition in the region perfused by the middle cerebral artery and its branches (see also Fig 1; scale bars are 500μm and
100μm; please note that animals with a high CAA load are depicted to demonstrate CAA distribution). (B–D) CAA quantiﬁcation
of neocortex, including the leptomeningeal vessels, revealed a signiﬁcant age-dependent increase between 23.5 and
27.5 months, which could be largely prevented by the application of the BACE1 inhibitor. The results are presented as CAA
score (B; Kruskal–Wallis H test, df = 2, H corrected for ties = 13.33, p = 0.0013; Dunn multiple comparisons test *p < 0.05,
**p < 0.01), which was calculated by multiplying CAA frequency (C; Kruskal–Wallis H test, df = 2, H corrected for ties = 13.33,
p = 0.0013; Dunn multiple comparisons test *p < 0.05, **p < 0.01) with CAA severity (D; Kruskal–Wallis H test, df = 2, H
corrected for ties = 15.37, p = 0.0005; Dunn multiple comparisons test *p < 0.05, ***p < 0.001). All data are represented as
group medians with interquartile range; n = 11, 17, and 19 for the 23.5, 27.5, and 27.5 BI groups, respectively.
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NB-360 has not been tested in humans; however,
exposures to NB-360 are very comparable to the BACE
inhibitor CNP520.36,37 CNP520 treatment of humans
(90mg/day, repeated dosing) resulted in ~1μM blood
levels, a blood concentration that is close to the concen-
tration of NB-360 in mice with the current dosing
FIGURE 5: Microgliosis, microhemorrhages, and vascular smooth muscle cell loss in β-site amyloid precursor protein cleaving enzyme
1 (BACE1)-inhibitor–treated mice. Female APPDutch mice were either fed with food pellets containing the BACE1 inhibitor NB-360 (BI;
n = 19) or control pellets (n = 17) for 4 months (same mice as in Figs 3, 4). (A, B) Cerebral amyloid angiopathy (CAA)–positive vessels
(Congo red [CR], red) revealed clustering of activated (hypertrophic) microglia (immunostaining for ionized calcium binding adapter
molecule 1, blue-black). Compared to the control mice (A), microglia clusteringwas reduced in the BI treatment group (B) consistent with
the reduced CAA in the BI-treated mice. Images depict part of the brain region perfused by the middle cerebral artery and its branches
(see also Fig 1). Scale bar is 200μm. (C) Quantiﬁcation (seeMaterials andMethods section for details) revealed a reduction of CR-positive
vessels with clusters of hypertrophic microglia in BI-treated mice compared to the controls (Mann–Whitney U test: U = 69.0, p = 0.0026;
median with interquartile range). (D) Microhemorrhages were assessed by counting and grading clusters of hemosiderin-positive microglia
in the neocortex including the leptomeningeal vessels (see Materials and Methods section for details). No signiﬁcant difference between
control and BI-treatedmice for the calculatedmicrohemorrhage score was found (Mann–WhitneyU test:U = 146.5, p = 0.64; median with
interquartile range). (E) Progressive loss of smooth muscle cells with increasing CAA. Double-stained vessels (smooth muscle actin [SMA],
green; aggregated β-amyloid peptides, red) of different CAA severity grades (grade 1–3; see Materials and Methods section for details).
Unaffected vessels (CAA0) depict a complete layer of smoothmuscle cells, andCAAgrade1 (CAA1) leads to a focal displacement of smooth
muscle cells. In CAA stage 3 (CAA3), there is a complete loss of the smoothmuscle cells. Scale bar is 20μm. (F) Quantiﬁcation of the smooth
muscle cells for vessels with different CAA grades (SMA area was normalized to the total SMA + CAA area per vessel; see Materials and
Methods section for details). A drastic decrease of smooth muscle cell staining with increasing CAA grade was found, and this was equally
true for both groups, that is, BI treatment and controls (2-way analysis of variance, CAA severity: df= 3, F = 513.45, p < 0.0001; treatment:
df = 1, F = 0.006, p = 0.94; mean and standard error of themean is indicated). This latter observation with the ﬁnding that (G–I) frequency
of all CAA severity gradeswas signiﬁcantly reduced in the BI treatedmice compared to the controlmice (n = 19 and17, respectively;Mann–
Whitney U test, CAA1: U = 89.0, p = 0.02; CAA2: U = 68.5, p = 0.002; CAA3: U = 71.0, p = 0.0017; median with interquartile range)
reveals that CAA-associated smoothmuscle cell loss was largely preventedby the BI treatment.
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scheme.36 Thus, the current dosing in mice appears well
in the exposure range that shows CSF Aβ reduction in
humans.
In conclusion, the robust prevention of CAA progres-
sion described here strongly supports testing Aβ-lowering
treatments in presymptomatic HCHWA-D mutation car-
riers. BACE1 inhibitors appear to be a reasonable choice pro-
vided the present ﬁndings (in females) can be generalized to
male mice and that recent controversies about their safety
proﬁles for long-term treatment38 can be resolved. For clini-
cal trials, recent promising imaging modalities such as posi-
tron emission tomography for CAA,39–41 functional
magnetic resonance imaging (MRI) for vascular
dysfunction,42 and MRI for detection of cerebral (micro)
bleeds and early blood-brain barrier breakdown43,44 in
HCHWA-D will be important requirements because CSF
Aβ—albeit a good readout for vascular amyloid deposition
and for target engagement—will be less optimal for assessing
CAA upon BACE1 inhibitor treatment or any other Aβ-
lowering therapies. Aβ-targeting clinical trials have so far
largely failed for a variety of reasons, one of which is the
uncertainty of Aβ’s precise role in AD pathogenesis.45,46 The
link between Aβ deposition in the vasculature and CAA and
associated lesions is more direct, thus increasing the chance
of success in Aβ-lowering trials in patients at risk of CAA.
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